Editor's note: Seeking Alpha is proud to welcome Sergio Gonzalez as a new contributing analyst. You can become one too! Share your best investment idea by submitting your article for review to our editors. Get published, earn money, and unlock exclusive SA Premium access.
CorMedix 2.0: New Leadership, New Approval, New Focus
Summary
- CorMedix is a biopharmaceutical company that has undergone a re-birth as it enters a new phase with FDA approval of its anti-infective catheter solution, DefenCath.
- The company has faced challenges in the past, including management issues and regulatory delays, but now warrants a fresh look and valuation as the company executes on commercialization.
- DefenCath offers a unique solution for preventing catheter-related bloodstream infections, with the potential to reduce costs and save lives.
I am a corporate strategy professional with work experience across industrials, energy, and technology. My primary investment interest is in biotech where I have over a decade of investment experience. My secondary investment interests are in dividend growth equities and business development companies (BDC). I enjoy writing and sharing my thoughts on business and life with others.
Analyst’s Disclosure:I/we have a beneficial long position in the shares of CRMD either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.